Caris Life Sciences boosts IPO price to raise $494 million
The cancer testing company claimed a valuation of about $5.9 billion, while selling 23.5 million shares under the Nasdaq ticker CAI at $21 apiece.
The cancer testing company claimed a valuation of about $5.9 billion, while selling 23.5 million shares under the Nasdaq ticker CAI at $21 apiece.
